Major diabetes drug study launches in pakistan
NCT ID NCT05164263
Summary
This study aims to monitor the real-world safety and effectiveness of the diabetes medication empagliflozin, taken with or without metformin, in Pakistani adults. It will follow 2000 participants for up to 6 months to track side effects and how well the drug controls blood sugar and weight. The goal is to gather practical experience on how these commonly used medications perform in everyday clinical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Agha Khan univeristy hospital
RECRUITINGNairobi, Kenya, Kenya
Contact
-
Kabul University of Medical Sciences(KUMS)
COMPLETEDKabul, Afghanistan, Afghanistan
-
Lagos University Teaching Hospital
RECRUITINGLagos, Nigeria, Nigeria
Contact
Contact
Contact
-
NHK
COMPLETEDKandy, Kandy, Sri Lanka
-
National hospital Sri Lanka
COMPLETEDColombo, Colombo, Sri Lanka
-
Umar Diabetes Foundation
COMPLETEDIslamabad, Pakistan
Conditions
Explore the condition pages connected to this study.